Sareum Holdings Plc - Company Profile
Powered by 
All the sales intelligence you need on Sareum Holdings Plc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Sareum Holdings Plc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Sareum Holdings Plc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Sareum Holdings Plc (Sareum) is a clinical-stage small molecule company. It is focused on developing kinase inhibitors for autoimmune diseases and cancer. The company’s pipeline targets the TYK/JAK cell signaling family, crucial for immune system regulation. Sareum’s lead program, SDC-1801, is a potent, selective TYK2/JAK1 inhibitor aimed at autoimmune diseases, particularly psoriasis. It is developing SDC-1802, a TYK2/JAK1 inhibitor for cancer and cancer immunotherapy. The company also holds a significant economic interest in SRA737, an oral, selective Checkpoint Kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA repair, currently in clinical trials for advanced cancers. Sareum is headquartered in Cambridge, the UK.
Headquarters
United Kingdom
Address
Unit 2a, Langford Arch, London Road, Pampisford, Cambridge, CB223FX
Website
www.sareum.com
Telephone
44 1223 497700
No of Employees
5
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
SAR (LON)
EPS
XYZ
Net Income (2025)
XYZ
-29.8%
(2025 vs 2024)
Market Cap*
$66.0M
Net Profit Margin (0 vs)
XYZ
0.0%
(2025 vs 2024)
* As of and is in US$
Sareum Holdings Plc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline: |
| SDC-1801 - Autoimmune Disease |
| SDC-1802 - Cancer Immunotherapy |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2020 | Contracts/Agreements | In March, the company has entered into global license agreement with a China-based specialty pharmaceutical company for its s FLT3+Aurora kinase inhibitor programme targeting blood cancers. |
| 2018 | Others | In May, Sareum regained worldwide rights to preclinical stage small molecule inhibitors of Aurora and FLT3 kinases in pre-clinical development targeting hematological cancers. |
| 2017 | Patent Grant | In December, the Japanese Patent Office granted a patent for inventions associated with Sareum’s TYK2 kinase inhibitor program. |
Competitor Comparison
| Key Parameters | Sareum Holdings Plc | Incyte Corp | Iovance Biotherapeutics Inc | Karyopharm Therapeutics Inc | Scancell Holdings Plc |
|---|---|---|---|---|---|
| Headquarters | United Kingdom | United States of America | United States of America | United States of America | United Kingdom |
| City | Cambridge | Wilmington | San Carlos | Newton | Oxford |
| State/Province | - | Delaware | California | Massachusetts | Oxfordshire |
| No. of Employees | 5 | 2,844 | 838 | 228 | 60 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Stephen Barry Parker | Chairman | Executive Board | 2016 | 68 |
| Timothy John Mitchell, Ph.D. | Director; Chief Operating Officer | Executive Board | 2004 | 66 |
| John Reader, Ph.D. | Chief Scientific Officer; Director | Executive Board | 2004 | 59 |
| Clive Birch | Secretary; Director | Executive Board | 2022 | 73 |
| Michael Owen, Ph.D. | Director | Non Executive Board | 2018 | 75 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer